2021 Symposium
|
2015 Symposium Slideshow2015 Symposium Highlights from MCC Industry Relations on Vimeo. Thank you to all that came and participated in the 2015 Symposium - we hope you enjoy the memories! 2015 Symposium Featured TalksPlease enjoy the featured talks below from our recent symposium. Thank you! Please note: These videos are for private viewing only. Any unintended use of the videos without consent is prohibited. Symposium Organizer WelcomeIda Deichaite, PhD UC San Diego Moores Cancer Center Moores Cancer Center WelcomeScott Lippman, MD UC San Diego Moores Cancer Center Dean, School of Medicine WelcomeDavid Brenner, MD UC San Diego School of Medicine Chancellor WelcomePradeep Khosla, PhD UC San Diego Finding the Money to Fund Translational ResearchRep. Scott Peters, Congressman Bob Klein, Klein Financial Corporation National Entrepreneurs Month Presented to the Roth FamilyPresented by Rep. Scott Peters, Congressman Duane Roth AwardPresented by Rep. Scott Peters, Congressman Awarded to Brian Druker, MD, OHSU Knight Cancer Institute Keynote Presentation: Imatinib as a Paradigm of Molecularly Targeted Cancer TherapiesBrian Druker, MD OHSU Knight Cancer Institute Drugging the Undrugable: KRASD. Lynn Kirkpatrick, PhD PHusis Therapeutics ePatients on the Front Lines: Precision Medicine, the FDA, and MeJanet Freeman-Daily, MS, ENG Patient Advocacy Keynote Presentation: Cancer Genomics: Turning Discovery into TranslationElaine Mardis, PhD The Genome Institute Washington University School of Medicine Advancing the Utility of Clinic Sequencing for MDSRafael Bejar, MD, PhD UC San Diego Moores Cancer Center A More Beautiful QuestionBrad Perkins, MD Human Longevity A novel bispecific antibody targeting EGFR and cMet with multiple mechanisms of actionMark Anderson, PhD Janssen Pharmaceuticals Napoleon in Rags and the Language that he Used: the New World of Immunotherapy in Head and Neck CancerEzra Cohen, MD UC San Diego Moores Cancer Center Melanoma Patients Path: Translations to the ClinicGregory Daniels, MD UC San Diego Moores Cancer Center Targeting PI3Kgamma and BTK to suppress tumor-associated inflammationJudith Varner, PhD UC San Diego Moores Cancer Center CIRM 2.0. Building a better stem cell agencyC. Randal Mills California Institute for Regenerative Medicine Patient's PerspectiveTheresa Blanda, Patient Catriona Jamieson, MD, PhD, UC San Diego Moores Cancer Center Combining VEGF inhibitors with strategies to manipulate the immune system in cancerNapoleone Ferrara, MD UC San Diego Moores Cancer Center Development of Next Generation Angiogenesis InhibitorsCharles Theuer, MD, PhD TRACON Pharmaceuticals Bringing Btk inhibition forwardDanelle James, MD, MAS Pharmacyclics Reversing Drug Resistance in Cancer StemnessDavid Cheresh, PhD UC San Diego Moores Cancer Center Preclinical and Clinical Cancer Stem Cell Detection and EliminationCatriona Jamieson, MD, PhD UC San Diego Moores Cancer Center 2015 SymposiumOur 11th Annual Moores Cancer Center Industry/Academia Translational Oncology Symposium took place on Thursday February 19, 2015. We thank all of our speakers and attendees for a successful event! We look forward to the collaborations that will blossom and future symposia. February 22, 2015
CIRM's Klein proposes $100B biomed program: Bob Klein describes his vision of how to increase biomedical funding to hasten discovery and commercialization of disease treatments. He spoke Thursday, Feb. 19, at the annual UCSD Moores Cancer Center symposium.
|
A novel bispecific antibody targeting EGFR and cMet with multiple mechanisms of action Mark Anderson, PhD Janssen Pharmaceuticals Advancing the Utility of Clinic Sequencing for MDS Rafael Bejar, MD, PhD Welcome and Overview David Brenner, MD Reversing Drug Resistance in Cancer Stemness David Cheresh, PhD Napoleon in Rags and the Language that he Used: the New World of Immunotherapy in Head and Neck Cancer Ezra Cohen, MD Targeting tumor-associated inflammation in cancer Lisa Coussens, PhD Melanoma Patients Path: Translations to the Clinic Gregory Daniels, MD Combining VEGF inhibitors with strategies to manipulate the immune system in cancer Napoleone Ferrara, MD ePatients on the Front Lines: Precision Medicine, the FDA, and Me Janet Freeman-Daily The Cancer Cell Map Initiative (CCMI) - Mapping the hallmark networks of cancer Trey Ideker, PhD Bringing Btk inhibition forward Danelle James, MD, MAS Pharmacyclics |
Preclinical and Clinical Cancer Stem Cell Detection and Elimination Catriona Jamieson, MD, PhD Welcome and Overview Pradeep Khosla, PhD Drugging the Undrugable: KRAS D. Lynn Kirkpatrick, PhD PHusis Therapeutics Inc. Finding the Money to Fund Translational Research Bob Klein Klein Financial Corporation Welcome and Overview Scott Lippman, MD CIRM 2.0. Building a better stem cell agency C. Randal Mills, PhD California Institute for Regenerative Medicine A More Beautiful Question Brad Perkins, MD Human Longevity, Inc. Engineering the immune system with chimeric antigen receptors to eradicate cancer Margo Roberts, PhD Kite Pharma Development of Next Generation Angiogenesis Inhibitors Charles Theuer, MD, PhD TRACON Pharmaceuticals Targeting PI3Kgamma and BTK to suppress tumor-associated inflammation Judith Varner, PhD |
“When you go to an international cancer symposium with 30,000 people, it’s hard to get to the real champion of a project and get their individualized attention. The Moores Cancer Center Translational Oncology Symposium is much more intimate. Industry and academia are on equal footing and there are plenty of opportunities for informal discussions when a lot of synergies develop and collaborations begin or grow.”
- Catriona Jamieson, Ph.D., M.D.,
Director of Stem Cell Research at Moores Cancer Center
The MCC Translational Oncology Symposium is designed as an international forum to foster introductions, stimulate productive conversations among people of complementary interests and galvanize collaborations that will have a profound impact on patient health. It’s a melding of minds in the field of cancer research. Represented will be many of the different skill sets needed to bring a new drug to market – from the lab, through the commercialization process to the patient’s bedside.
Hear from global thought leaders in some of the most promising frontiers of research and treatment, including immunotherapy, antibodies and personalized medicine. Meet top academic researchers, renowned clinicians, and top business development professionals and scientists from the world’s leading pharmaceutical companies and innovative biotechnology companies working in oncology.
In a global environment of budget cuts, including investment in scientific research, industry/academia collaborations are crucial to leverage resources and expertise. In its first ten years, the MCC Translational Oncology Symposium has shown great success in forging collaborations that are speeding drug development times and saving lives:
- Collaboration between Pfizer and MCC led to a multisite international clinical trial of a sonic hedgehog inhibitor. One patient who was told she had just months to live is alive three years later and has undergone a bone marrow transplant after participating in the trial.
- Collaboration between San Diego-based TargeGen, MCC and Stanford University, which sped the development of a JAK2 inhibitor and led to the acquisition of TargeGen.
Symposium Organizers and Chairs
Symposium Organizers:Scott Lippman, MD Symposium Chair:David Cheresh, PhD |
Ida Deichaite, PhD Symposium Co-Chair:Catriona Jamieson, MD, PhD |